

Novel Protein Sequencing Platform

Kuval Ray, Marialena Varimpopioti and Taylor Pistone


Competitive Advantage

Features	Mass Spectrometry	Other Technologies	Glyphic
Efficient in time and capital	✗	✓	✓
Detection of all post-translational modifications	✓	✗	✓
Works well with low abundance of proteins	✗	✗	✓
High sensitivity and throughput	✗	✗	✓

Possibilities with our technology

- Personalized antibody treatment
- Development of novel therapeutics and diagnostics
- Deeper understanding of human biology
- Protein sequencing from limited samples


Our Solution



Antibodies & Neo Antigens

- Animals produce 10^{12} Antibodies and scientist only detect 10^5 with current methods
- Mutated Antigens are specific to a patient's cancer
- Currently, both workflows require DNA sequencing and protein prediction to understand Antibody sequence

Market Opportunity



Source: Grand View Research

Timeline



Interested in working with us?

Contact us at Daniel@glyphic.bio or Joshua@glyphic.bio